Blog

It’s Complicated

Reading Time: 8 Minutes

Published March 28, 2026

Morning Report — Not Your Typical Medical Newsletter

We get it, you see a lot of medical newsletters, so hear us out. Once a month, we’ll highlight important medical news sprinkled with witty commentary, fun facts, giveaways, and more… because learning should be fun! Subscribe to receive the Morning Report directly.

Good morning! When you and a colleague disagree, maybe you send a pointed email, request committee review, or passive-aggressively cite meta-analyses on rounds. In 18th-century Britain, the dueling craze (1770-1820) expected physicians, as “gentlemen,” to settle disputes at 10 paces—with gunpowder, not footnotes.

Naturally, this uncivilized ritual followed a code,The British Code of Duel, meant to distinguish dueling from murder. Notable provisions:

Answer any “justifiable” duel challenge or risk social exile.
Fire by signal and “at random”; careful aim is considered unsporting.
Ensure a surgeon attends but stays out of sight—to avoid accessory charges.
Apply the first dressing to whoever received the first fire.

While today’s morbidity meetings are mercifully metaphorical, spare a thought for your predecessors who defended their standing with pistols at dawn.

Weight, Menopause, and Hormone Therapy Complicate Breast Cancer Risk

CANCER CONCLUSIONS

Obesity is linked to higher breast cancer risk, but a new large systematic review and meta-analysisof >2 million women reminds us that the biology isn’t so tidy. Risk shifts across BMI categories and breast cancer subtypes, with menopausal status as the fulcrum—tipping risk in different directions—and menopause hormone therapy (MHT) adding another layer.

The details matter, so lace up your boots—we’re heading into the weeds.

Postmenopausal women

Overweight and especially obesity increase estrogen receptor (ER)-positive risk.
Risk is highest in women not using MHT.
Overweight modestly increases HER2-positive risk; obesity is less consistent.
There's no clear signal for ER-negative or triple-negative disease.

Premenopausal women

Overweight lowers ER-positive risk, with similar but weaker trends for obesity.
Overweight increases ER-negative and triple-negative risk.
HER2-positive risk shows no consistent association.

Overall (mixed population)

Obesity modestly increases ER-positive risk; overweight doesn’t.
Triple-negative disease remains largely BMI-agnostic.

Limitations abound

First, keep in mind the predominantly retrospective study designs and heterogeneity across populations, methods, and subtype classification. Then there’s BMI—this crude metric captures weight at a single time point, ignoring fat distribution and change over time. And in many studies, it’s self-reported—a polite way of saying accuracy may be questionable.

Key takeaways

This study sharpens how we think about obesity, menopause, and MHT in breast cancer risk. For postmenopausal patients, lower adiposity still matters, particularly for ER-positive disease. And for appropriate candidates, MHT deserves a thoughtful look. As Dr. Pamela Kushner, Clinical Professor at UC Irvine Medical Center, puts it, “Hormones remain underused in medicine, and studies like this remind us that their role in disease risk is more nuanced than many of us realize.” This study may help MHT shed some of the baggage from that early-2000s scare—if only good data carried as much weight as bad headlines.

For more education on breast cancer, check out this CME podcast: Breast Cancer: Increased Incidence Doesn’t Mean Increased Mortality

Time to Close the Fasting Window?

DIETARY DIGEST

Intermittent fasting, the TikTok darling of diet trends, has delivered mixed results under the bright lights of clinical trials. The challenge is rigorously studying an obesity intervention defined more loosely than a New Year’s resolution. Approaches range from alternate-day fasting to periodic fasting to time-restricted eating, muddying comparisons. A new Cochrane review aims to cut through the variability and assess whether the hype holds up.

Much ado about fasting

The review analyzed 22 randomized trials involving nearly 2,000 adults across multiple countries, comparing intermittent fasting with standard dietary advice or no structured intervention. Across studies, intermittent fasting did not produce clinically meaningful additional weight loss—it was no better than standard diet advice and at times only marginally better than doing nothing at all, or just planning to “start Monday.”

As with most nutrition research, these findings come with more asterisks than a user agreement. Trials tended to be small, short-term, and of variable quality. Studies inconsistently measured adherence and drew participants predominantly from White, high-income populations. Outcomes often relied on self-reported behaviors. Notably, none assessed participant satisfaction, so we don’t know who’d make it past Monday without a clipboard nearby.

Key takeaways

Intermittent fasting may be on the menu for patients who prefer it—but the hype may have outpaced the science. While influencers slot it somewhere between cold plunges and red-light goggles in the “THIS CHANGED MY LIFE!” hierarchy, evidence shows it may not stack up to the claims. Some experts argue the modest results likely reflect reduced physical activity during fasting and the broader reality that sustained weight loss remains difficult without pharmacologic support. The takeaway is simple: If patients can stick with it, intermittent fasting is reasonable—but it falls short of a breakthrough, despite what algorithms insist.

For more education on obesity management, check out this CME activity: Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity

Chocolate Trial Unwraps Insights into Biological Aging

SPECIAL CONTRIBUTOR—FRANK DOMINO, MD

If Willy Wonka ran a clinical trial, it might look a lot like COSMOS: free chocolate, big promises, and an unexpected outcome. Researchers from the long-running study—partly funded, of course, by the chocolatiers at Mars (makers of M&M’s and Snickers)—set out to determine whether cocoa supplementation or a daily multivitamin (MVI) could improve health outcomes.

Nearly 1,000 participants with an average age of 70 received either cocoa extract, an MVI, a combination of both, or a placebo daily for two years in this ancillary substudy of COSMOS. Sadly, the parent trial did not show evidence that cocoa supplementation makes us live longer, but iffy correlations from a separate analysis hinted that MVI supplementation in older adultsmightimprove memory.

Might.

Just released is the latest data from the COSMOS trial suggesting that MVIs can alter our “epigenetic aging clocks,” which are surrogate markers of biological aging. It found MVIs “reduced the rate of increase of these markers,” suggesting slower aging.

However, this did not demonstrate improvements in clinical outcomes like living longer or better. Instead, it reflects changes in epigenetic biomarkers—not patient-centered outcomes. That is it.

Key takeaways

MVIs may be the Swiss Army knife of supplementation. But want to know what they haven’t been shown to improve? Cardiovascular outcomes, physical functioning, falls, bone health, cancer risk—or (my personal favorite) all-cause mortality.

My recommendation? Encourage patients to spend their money on some headphones and go for a daily walk to lower their risks for CVD, falls, cancer, and all-cause mortality.

Interested in more healthcare news? Here are some other articles we don’t want you to miss:

Morning Report is written by:

Alissa Scott, Author
Aylin Madore, MD, MEd, Editor
Margaret Oliverio, MD, Editor
Ariel Reinish, MD, MEd, Editor
Emily Ruge, Editor

Did You Enjoy This Issue of Morning Report?

Absolutely! | For the most part | Not at all

Click above, or share your feedback via email. Drop us an email at morningreport@pri-med.com to let us know how we’re doing.

Please note that the summaries in Morning Report are intended to provide clinicians with a brief overview of an article, and while we do our best to select the most salient points, we ask that you please read the full article linked in each summary for clarification before making any practice-changing decisions.

Enjoying Morning Report? Share It with Colleagues!

Is Morning Report for you? It is if you’re someone who needs quick-hitting, accurate medical news—but with some flair.

You don’t just need to know about the latest metabolism study—you also need to know how it parallels an Alanis Morissette hit. If you’re reading about acupuncture treatment, you need us to skip the needle puns and get straight to the point. We keep things simple, but when we do get into the scientific weeds, we always remind you to check for ticks.

Subscribe to receive Morning Report directly in your inbox the first Saturday of every month.